Comparison of NN5401 With Insulin Glargine in Insulin Naive Subjects With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 296 participants.

Also called NCT01272193

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 296 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01272193
Other papers using this trial's data
  • Superior glycaemic control with once-daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trial Diabetes, obesity & metabolism, 2013-09 DOI, PubMed 23557077

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01272193. Randomized; no masking; primary purpose treatment. Start 2011-01 (registry gives no type); primary completion 2011-09 (actual). Results posted on 2015-11-23.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparison of NN5401 With Insulin Glargine in Insulin Naive Subjects With Type 2 Diabetes
Acronym
BOOST™
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
insulin degludec/insulin aspart
Intervention (Drug)
insulin glargine
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct01272193
Content hash
f5e470958afeb9a02b96ec9af22cc9c11ba43e159040e3ffff5e977ef3a82814